A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection.
L. M. Coria, L. M. Saposnik, C. Pueblas Castro, E. F. Castro, L. A. Bruno, W. B. Stone, P. S. Perez, M. L. Darriba, L. B. Chemes, J. Alcain, I. Mazzitelli, A. Varese, M. Salvatori, A. J. Auguste, D. E. Alvarez, , J. Cassataro
This paper evaluates RBD-based vaccine formulations with different adjuvants, finding that U-Omp19+Alum significantly increases neutralizing antibodies, B cells, and provides protection against SARS-CoV-2.
bioRxiv · Dec 7, 2021 · PreprintImmunology